News Vertex Pharmaceuticals Incorporated

Stocks

VRTX

US92532F1003

Pharmaceuticals

Real-time Estimate Cboe BZX 12:20:22 24/10/2026 am IST			5-day change	1st Jan Change
525.52 ^USD	-1.80%		+5.23%	+16.00%

22/10	5 Healthcare Stocks to Watch as Investors Look Beyond Big Tech
21/10	Vertex Pharmaceuticals Incorporated Announces Appointment of Daniel Brennan as Member of the Board of Directors, Audit and Finance Committee	CI

All News

Mentions Relevance

11:13pm	Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 2026	BU
21/10	Vertex Pharmaceuticals Incorporated Announces Appointment of Daniel Brennan as Member of the Board of Directors, Audit and Finance Committee	CI
21/10	Vertex Appoints Daniel Brennan to its Board of Directors	BU
15/10	Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $654 From $653	MT
09/10	Vertex Pharmaceuticals Says Alyftrek Delivers Pancreatic Function Recovery in Some Children	MT
09/10	Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference	BU
09/10	Vertex Pharmaceuticals Incorporated Presents New Interim Data on Alyftrek in Children Ages 2 to 5 Years At the North American Cystic Fibrosis Conference	CI
08/10	RBC Lifts Price Target on Vertex Pharmaceuticals to $576 From $570, Keeps Outperform Rating	MT
08/10	Vertex to Announce Third Quarter 2026 Financial Results November 2nd	BU
07/10	Vertex Pharmaceuticals Incorporated Presents at Bank of America Global Healthcare Conference 2026, Sep-23-2026 09:05 AM
28/09	UBS Raises Vertex Pharmaceuticals Price Target to $615 From $585, Maintains Buy Rating	MT
23/09	TD Cowen Adjusts PT on Vertex Pharmaceuticals to $550 From $525, Maintains Buy Rating	MT
23/09	Jefferies Adjusts Price Target on Vertex Pharmaceuticals to $640 From $633, Maintains Buy Rating	MT
22/09	Vertex Pharmaceuticals Incorporated Announces Positive Results From Phase 2b AMPLIFIED Study Of Inaxaplin And Completes Enrollment In The Phase 2/3 AMPLITUDE Trial	CI
22/09	Vertex Pharmaceuticals Reports Positive Results for Inaxaplin Kidney Disease Trial	MT
22/09	Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial	BU
15/09	Vertex Partners With World Champion Skier Lindsey Vonn to Raise Awareness of JOURNAVX®, a Non-Opioid Medicine Approved for the Treatment of Moderate-to-Severe Acute Pain	BU
14/09	Vertex Pharmaceuticals Incorporated Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-14-2026 07:00 AM
11/09	Vertex Pharmaceuticals Incorporated Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02:10 PM
10/09	Vertex Pharmaceuticals Incorporated Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 04:30 PM
02/09	Evercore ISI Adjusts Vertex Pharmaceuticals Price Target to $600 From $535, Maintains Outperform Rating	MT
02/09	Vertex Pharmaceuticals Incorporated Announces Chief Financial Officer Changes, Effective January 1, 2027	CI
02/09	Vertex Pharmaceuticals Incorporated Appoints Jonathan Poole as Executive Vice President, Effective January 1, 2027	CI
01/09	Vertex Names Jonathan Poole Finance Chief as Crinetics Buy Closes	DJ
01/09	Vertex Pharmaceuticals Closes Crinetics Pharmaceuticals Acquisition	MT